Lapatinib (CAS 231277-92-2) Suppliers and Product Information

Lapatinib is an oral tyrosine kinase inhibitor that targets both EGFR (ErbB1) and HER2 (ErbB2) receptors. It is used in the treatment of advanced or metastatic breast cancer with overexpression of HER2. Lapatinib acts by inhibiting the intracellular tyrosine kinase domains of these receptors, preventing tumor cell growth and proliferation.

Frequently Asked Questions about Lapatinib

Q: What is the primary use of Lapatinib?

A: Lapatinib is primarily used in combination with capecitabine to treat patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including anthracyclines, taxanes, and trastuzumab.

Q: How does Lapatinib work?

A: Lapatinib works by inhibiting the tyrosine kinase activity of both EGFR (ErbB1) and HER2 (ErbB2) receptors. It blocks the intracellular ATP binding sites, preventing tumor cell phosphorylation and activation, thus inhibiting cancer cell growth and proliferation.

Q: What are the advantages of Lapatinib over single-target therapies?

A: Lapatinib's ability to simultaneously inhibit both Her1 and Her2 receptors results in a more significant biological effect in inhibiting tumor cell proliferation and growth compared to therapies that target only one receptor.

Q: Is Lapatinib effective in Herceptin-resistant patients?

A: Yes, clinical trials have shown that Lapatinib can effectively treat HER2-positive cancer patients who have developed resistance to Herceptin (trastuzumab).